Posted by Michael Wonder on 29 Mar 2022
Ondexxya approved in Japan for reversal of acute major bleeds in patients on factor Xa inhibitors
29 March 2022 - Ondexxya is the first approved reversal agent specifically for factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Ondexxya (andexanet alfa) has been approved in Japan for patients treated with the factor Xa inhibitors apixaban, rivaroxaban or edoxaban, when reversal of anti-coagulation is needed due to life-threatening or uncontrolled bleeding.
